迷幻剂：科学、疗法与人类心智
摘要
约翰斯·霍普金斯大学迷幻剂研究领域的领军人物 Matthew Johnson 对迷幻剂进行了全面综述，内容涵盖药理学与安全性、治疗潜力，以及成瘾的神经科学。对话涉及psilocybin（裸盖菇素）和LSD等经典迷幻剂、DMT 的独特属性，以及理解成瘾的行为经济学框架。
核心要点
- 经典迷幻剂（裸盖菇素、LSD、麦司卡林、DMT）在生理层面具有极高的安全性 —— 对大多数健康人而言，目前尚无已知致死剂量，这与几乎所有其他精神活性物质（包括咖啡因和阿司匹林）形成鲜明对比。
- 经典迷幻剂不具成瘾性，这在人们出于娱乐目的选择使用的物质中几乎是前所未有的。
- 迷幻剂的主要风险是”行为毒性” —— 即在严重中毒状态下做出危险行为（如误闯车流），而非器官损伤或过量中毒。
- 心态与环境至关重要：一个人进入体验时所持有的既有信念、语言和文化框架，会深刻影响体验的内容。
- 裸盖菇素和 LSD 在治疗成瘾、抑郁以及癌症相关焦虑方面展现出强大的治疗前景，相关研究正获得越来越多的慈善资金支持。
- DMT 和 5-MeO-DMT 代表迷幻谱系中最极端的一端，能产生自我消解与实体相遇的体验，远超典型的高剂量裸盖菇素或 LSD 疗程。
- 成瘾最好通过两个视角来理解：某种物质相对于其他生活奖励的相对奖励价值，以及delayed discounting（延迟折现，即倾向于高估即时奖励而低估长期后果的心理）。
- 尼古丁/烟草是现代社会中最危险的毒品（以死亡率衡量），每年造成约 50 万美国人死亡——是酒精致死人数的四倍。
- **迷幻剂疗程后数日内的Neuroplasticity 神经可塑性（神经可塑性）**可能是其产生治疗效果的关键，但这一领域仍处于积极研究阶段。
详细笔记
什么是迷幻剂？
经典迷幻剂具有共同的作用机制：
- 它们作为血清素 2A 受体的激动剂发挥作用
- 包括：psilocybin（蘑菇）、LSD、DMT（死藤水、烟吸形式）、麦司卡林（佩奥特仙人掌、圣佩德罗仙人掌）
- 从化学角度可分为苯乙胺类、色胺类和麦角林类——但以受体活性进行分类更具意义
广义迷幻剂（药理机制不同，主观效果有重叠）：
- MDMA：作用于突触前，向突触大量释放血清素；成瘾性强于经典迷幻剂，但远低于可卡因；高剂量或频繁使用存在对血清素系统造成长期损伤的真实风险
- 氯胺酮、PCP、伊博格碱：机制各异，有时被非正式地归类为迷幻剂
- 大麻：历史上被称为”轻度迷幻剂”，尤其对初次使用者而言
所有迷幻剂的共同特征：对现实感和自我感的强烈改变。
经典迷幻剂的安全性
- 对于裸盖菇素或 LSD，目前尚无针对健康个体的已知致死剂量
- 理论上，一个人即使摄入有效剂量的 1,000 倍，也不会出现器官损伤、呼吸抑制或死亡
- 对比：阿司匹林、咖啡因、可卡因均有明确的致死剂量
- 例外情况：轻度心血管效应（血压轻度升高）——对严重心脏病患者存在风险
- 主要风险：行为毒性——在深度中毒状态下采取危险行动
- 经典迷幻剂不具成瘾性；与几乎所有其他精神活性物质不同，每日使用的情况极为罕见
DMT 与 5-MeO-DMT
- 代表现有最极端的迷幻体验
- 烟吸/汽化 DMT 的起效速度：首次呼出后数秒内开始起效；完整的”突破”通常需要约 3 大口吸入
- 这一过程被描述为从零加速至巅峰体验，仅需数秒——比任何其他给药途径都更快
- 突破剂量：从”深度改变但仍处于此现实”过渡至一个看似独立存在的现实
- 常见报告：与自主实体相遇（被描述为精灵、外星人、动物或抽象存在）；进行交流；感觉从更高智慧处接收信息
- Johnson 的解读：实体相遇很可能反映的是原型心理结构，并受文化先验影响着色，而非必然是字面意义上的外部存在——这可能是心智在处理压倒性信息时对隐喻的运用
- 整个体验全程保持记忆，与麻醉剂或高剂量酒精导致的记忆缺失不同
- 5-MeO-DMT 被许多有经验的使用者认为其强度比标准 DMT 高出数个数量级
治疗应用
- 当前研究重点：治疗成瘾（戒烟）、抑郁、PTSD（MDMA）以及癌症相关的存在性困境
- 大部分资金来源于慈善机构（而非政府）
- 来自癌症患者研究的关键洞见：患者在理智上”知道”应该拥抱生命，但一次裸盖菇素疗程让他们真正感受到了这一点——这是认知层面的知晓与身体层面的理解之间的区别
- 整合（疗程结束后的阶段）被认为对治疗效果至关重要；这是洞见被处理和应用的时期
- 疗程后的**Neuroplasticity 神经可塑性（神经可塑性）**已在动物实验中被观察到，在人类中亦有推测，可能是治疗效果的基础机制
- Johnson 已获得 Heffter 研究所的资助，用于即将开展的 LSD 研究
迷幻剂与创造力/认知增强
- 历史轶事：Kerry Mullis（诺贝尔奖得主，PCR 发明者）将其成就归功于迷幻体验；硅谷文化受迷幻剂影响深远
- 早期（1960 年代末至 70 年代）研究给建筑师和工程师服用中等剂量（约 100 微克 LSD），让他们致力于解决悬而未决的问题——结果颇有希望，但方法论存在缺陷
- 推测机制：减少根深蒂固的启发式思维和既有假设；提升思维灵活性与开放性
- 风险：同时也会产生假阳性——将本不应关联的点连接起来
- Johnson 的假设：高剂量疗程结合整合（而非在疗程中工作）对于创造性突破最具价值
- 带入体验中的语言和概念框架（“先验”）会深刻塑造所产生的洞见
迷幻体验的神经科学
- 迷幻剂会导致大脑各区域之间发生大量非典型通讯，而这些区域在通常情况下并不相互通讯
- 这种增强的连通性可能既是新颖洞见的基础，也是假阳性的根源
- 体验难以用语言描述；测量依赖经过心理测量学验证的问卷
- Ego dissolution（自我消解）：心理层面的自我建构的丧失；在经典迷幻剂中更为常见，尤其是 DMT/5-MeO-DMT；在 MDMA 中罕见
- 本体论层面的转变（例如转向唯心主义，或相信意识是根本性的）是可能发生的，但很可能受到个人既有世界观的强烈影响
成瘾：行为经济学框架
成瘾的两个核心维度：
-
相对奖励价值：该物质与其他奖励（人际关系、职业发展、健康）相比如何竞争？当药物奖励持续压倒亲社会奖励时，成瘾便随之出现。
-
Delayed discounting（延迟折现）：相对于即时奖励，对未来奖励进行贬值的倾向。成瘾人群表现出更陡峭的双曲折现曲线——倾向于选择较小的即时奖励而非较大的延迟奖励。
- 人类和大多数动物的折现方式是双曲折现（而非指数折现），这会导致偏好逆转：同一个人在治疗师办公室时真诚地想要戒断，而当药物触手可及时又真诚地想要使用。
- 这解释了”贪睡按钮”现象，以及为何在杂货店比站在敞开的冰箱前更容易自控。
核心洞见：成瘾不仅仅是”高奖励”，而是在可用替代选项的背景下的相对奖励。贫困、失业和受教育程度不足会减少竞争性奖励，使物质的相对奖励价值更高。
毒品政策
- 尼古丁/烟草是迄今最致命的毒品：美国每年约 50 万人死亡，全球约 500 至 600 万——是酒精的 4 倍
- 对香烟征收重税可减少青少年吸烟，但可能通过消耗收入而不减少使用，对低收入的深度成瘾者造成伤害
- 安全注射点获得公共卫生数据支持；没有可信证据表明它们会增加
English Original 英文原文
Psychedelics: Science, Therapy, and the Human Mind
Summary
Matthew Johnson, a leading psychedelics researcher at Johns Hopkins, provides a comprehensive overview of psychedelics — from their pharmacology and safety profiles to their therapeutic potential and the neuroscience of addiction. The conversation covers classic psychedelics like psilocybin and LSD, the unique properties of DMT, and behavioral economic frameworks for understanding addiction.
Key Takeaways
- Classic psychedelics (psilocybin, LSD, mescaline, DMT) are physiologically extraordinarily safe — there is no known lethal overdose for most healthy people, unlike nearly every other psychoactive substance including caffeine and aspirin.
- Classic psychedelics are non-addictive, which is nearly unprecedented among substances people choose to take recreationally.
- The primary risk of psychedelics is “behavioral toxicity” — doing something dangerous (e.g., wandering into traffic) while severely intoxicated, not organ damage or overdose.
- Set and setting matter enormously: the prior beliefs, language, and cultural frameworks a person brings into an experience strongly color its content.
- Psilocybin and LSD show strong therapeutic promise for addiction, depression, and cancer-related anxiety, with research increasingly well-funded through philanthropy.
- DMT and 5-MeO-DMT represent the most extreme end of the psychedelic spectrum, producing experiences of ego dissolution and entity encounters far beyond typical high-dose psilocybin or LSD sessions.
- Addiction is best understood through two lenses: the relative reward value of a substance compared to other life rewards, and delayed discounting (the tendency to overvalue immediate rewards vs. long-term consequences).
- Nicotine/tobacco is the most dangerous drug in modern society by mortality, killing ~500,000 Americans annually — four times more than alcohol.
- Post-experience Neuroplasticity 神经可塑性 in the days following a psychedelic session may be key to its therapeutic effects, though this remains under active study.
Detailed Notes
What Are Psychedelics?
Classic psychedelics share a common mechanism of action:
- They act as agonists at the serotonin 2A receptor
- Includes: psilocybin (mushrooms), LSD, DMT (ayahuasca, smoked), mescaline (peyote, San Pedro cactus)
- Can be organized chemically as phenethylamines, tryptamines, and ergolines — but receptor activity is the more meaningful classification
Broader psychedelics (different pharmacology, overlapping subjective effects):
- MDMA: works presynaptically, flooding synapses with serotonin; more addictive than classic psychedelics but far less than cocaine; carries real risk of long-term serotonin system damage at high/frequent doses
- Ketamine, PCP, ibogaine: distinct mechanisms, sometimes grouped informally as psychedelics
- Cannabis: historically called a “minor psychedelic,” particularly in naive users
What unifies all psychedelics: strong alteration of one’s sense of reality and sense of self.
Safety Profile of Classic Psychedelics
- No known lethal dose for psilocybin or LSD in otherwise healthy individuals
- A person could theoretically take 1,000x the effective dose without organ damage, respiratory depression, or death
- Contrast: aspirin, caffeine, cocaine all have well-defined lethal doses
- Exception: modest cardiovascular effects (slight blood pressure increase) — a risk for people with severe heart disease
- Main risk: behavioral toxicity — acting dangerously while profoundly intoxicated
- Classic psychedelics are non-addictive; daily use is essentially unheard of, unlike nearly all other psychoactive substances
DMT and 5-MeO-DMT
- Represent the most extreme psychedelic experiences available
- Smoked/vaporized DMT onset: effects begin within seconds of first exhalation; full “breakthrough” typically requires ~3 large inhalations
- Progression is described as acceleration from zero to peak experience in seconds — faster than any other route
- Breakthrough dose: transition from “profoundly altered but still in this reality” to a seemingly separate reality
- Common reports: encounters with autonomous entities (described variously as elves, aliens, animals, or abstract beings); communication; sense of receiving information from a higher intelligence
- Johnson’s interpretation: entity encounters likely reflect archetypal psychological structures colored by cultural priors, not necessarily literal external beings — possibly the mind’s use of metaphor to process overwhelming information
- The experience is fully memorable throughout, unlike anesthetics or high-dose alcohol, which cause amnesia
- 5-MeO-DMT is considered by many experienced users to be orders of magnitude more intense than standard DMT
Therapeutic Applications
- Current research focus: treating addiction (smoking cessation), depression, PTSD (MDMA), and cancer-related existential distress
- Most funding is philanthropic (not government-sourced)
- Key insight from cancer patient research: patients “knew” intellectually they should embrace life, but a psilocybin session allowed them to feel it — a distinction between cognitive knowledge and embodied understanding
- Integration (the period after a session) is considered critical to therapeutic outcomes; this is when insights are processed and applied
- Post-session Neuroplasticity 神经可塑性 has been observed in animals and is suspected in humans, possibly underlying therapeutic effects
- Johnson has received a grant from the Heffter Research Institute for an upcoming LSD study
Psychedelics and Creative/Cognitive Enhancement
- Historical anecdotes: Kerry Mullis (Nobel Prize, PCR inventor) credited psychedelic experiences; silicon valley culture widely influenced by psychedelics
- Early (late 1960s–70s) research gave architects and engineers moderate doses (~100 mcg LSD) and had them work on unsolved problems — results were promising but methodologically weak
- Proposed mechanism: reduction of entrenched heuristics and prior assumptions; increased mental flexibility and openness
- Risk: also produces false positives — connecting dots that shouldn’t be connected
- Johnson’s hypothesis: high-dose sessions followed by integration (not working during the session) are likely most valuable for creative breakthroughs
- Language and conceptual frameworks brought into the experience (“priors”) heavily shape what insights emerge
The Neuroscience of the Psychedelic Experience
- Psychedelics cause massively atypical communication between brain regions that don’t normally communicate
- This increased connectivity may underlie both novel insights and false positives
- Experiences resist verbal description; measurement relies on psychometrically validated questionnaires
- Ego dissolution: loss of the psychological construct of self; more common with classic psychedelics and especially DMT/5-MeO-DMT; rare with MDMA
- Ontological shifts (e.g., toward idealism or belief in consciousness as fundamental) are possible but are likely influenced heavily by a person’s prior worldview
Addiction: A Behavioral Economics Framework
Two core dimensions of addiction:
-
Relative reward value: How does the substance compete with other rewards (relationships, career, health)? Addiction emerges when drug reward consistently dominates over pro-social rewards.
-
Delayed discounting: The tendency to devalue future rewards relative to immediate ones. Addicted populations show steeper hyperbolic discounting curves — preferring smaller immediate rewards over larger delayed ones.
- Humans and most animals discount hyperbolically (not exponentially), causing preference reversals: the same person sincerely wants to quit when in a therapist’s office, then sincerely wants to use when the drug is immediately available.
- This explains the “snooze button” phenomenon and why self-control is easier at the grocery store than in front of an open fridge.
Key insight: Addiction is not simply “high reward” but relative reward in the context of available alternatives. Poverty, lack of employment, and lack of education reduce competing rewards, making substances relatively more rewarding.
Drug Policy
- Nicotine/tobacco is the deadliest drug by far: ~500,000 US deaths/year, ~5–6 million globally — 4x more than alcohol
- Heavy taxation of cigarettes reduces adolescent smoking but can harm low-income, deeply addicted users by consuming income without reducing use
- Safe injection sites are supported by public health data; no credible evidence they increase initiation of